Inactive Instrument

Other languages EntreMed Inc Nasdaq

Equities

US29382F2020

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 28	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	Top Midday Gainers	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Top Midday Gainers	Mar. 05
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell	Mar. 05
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Mar. 05
Top Premarket Gainers	Mar. 05
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China	Mar. 05
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd	Feb. 29
Casi Pharmaceuticals Announces First Dose of Folotyn in China	Feb. 16
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer	Feb. 12
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer	Jan. 30
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd	Dec. 08
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
CASI Pharmaceuticals Acquires Intellectual Property Rights to Cleave Therapeutics' Drug Candidate CB-5339	23-07-20
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26
CASI, Cleave Say China Drug Regulator Approves Clinical Trial Application for CB-5339 in Patients With Multiple Myeloma	23-01-06
CASI Pharmaceuticals, Inc. Announces Clinical Trial Application Approval for CB-5339 in Patients with Multiple Myeloma in China	23-01-06
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
CASI Pharmaceuticals, BioInvent Dose First Patient in Trial of Combination Treatment for Non-Hodgkin's Lymphoma	22-09-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages EntreMed Inc Nasdaq

Equities

US29382F2020

Other languages

Filters